FPS
BIO icon

Fieldpoint Private Securities’s Bio-Rad Laboratories Class A BIO Stock Holding History

Fieldpoint Private Securities’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$15K Sell
30
-60
-67% -$31.2K ﹤0.01% 650
2022
Q1 		$51K Buy
90
+15
+20% +$9.04K 0.01% 588
2021
Q4 		$57K Hold
75
– – 0.01% 566
2021
Q3 		$56K Hold
75
– – 0.01% 544
2021
Q2 		$57K Hold
75
– – 0.01% 543
2021
Q1 		$43K Hold
75
– – 0.01% 602
2020
Q4 		$44K Buy
+75
New +$42.7K 0.01% 496

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Fieldpoint Private Securities's BIO Position: Q2 2022 in Review

Fieldpoint Private Securities reduced its Bio-Rad Laboratories Class A (BIO) stake by 67% in Q2 2022, selling an estimated $31.2K and leaving 30 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #650.

Fieldpoint Private Securities first reported a position in BIO in Q4 2020 and has held it in 7 quarters since. The position peaked at $57K in Q4 2021. 501 funds tracked by Wall St. Rank hold BIO as of Q2 2022.

  • Fieldpoint Private Securities held 30 shares of Bio-Rad Laboratories Class A worth $15K as of Q2 2022.
  • Fieldpoint Private Securities sold 60 Bio-Rad Laboratories Class A shares in Q2 2022, an estimated $31.2K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Fieldpoint Private Securities's portfolio in Q2 2022, its #650 holding.
  • Fieldpoint Private Securities first reported a position in Bio-Rad Laboratories Class A in Q4 2020 and has held it in 7 quarters since.
  • Fieldpoint Private Securities's Bio-Rad Laboratories Class A position peaked at $57K in Q4 2021.
  • 501 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2022.

Based on Fieldpoint Private Securities's 13F filing for Q2 2022, filed 5 Aug 2022.